2016 went out like a lamb in the bio­phar­ma M&A world. Will it roar back in 2017? Plus, top 10 deals

Deal­mak­ers ev­i­dent­ly spent the fourth quar­ter of 2016 large­ly in hi­ber­na­tion as they wait­ed out a big US elec­tion cy­cle that seemed to raise more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.